UNSPSC 51141591: Donepezil oxalate

This classification denotes an acetylcholinesterase inhibitor C24H29NO3.C2H2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SLF7M28SI5, chemically known as 1h-inden-1-one, 2,3-dihydro-5,6-dimethoxyl-2-((1-(phenylmethyl)-4-piperidinyl)methyl)-, ethanedoioate (1:1), but more generally known as donepezil oxalate, which bears US NIH Compound Identifier 11397232. Most nations, for tariff and trade purposes, schedule donepezil oxalate under HS 29333999 and SITC 51574.

As of Q4 2014, DONEPEZIL OXALATE remains US FDA's Preferred Term for this commodity. Donepezil oxalate bears US NLM identifiers UMLS ID C2828323 and NCI Concept Code C87489. SMILES: COC1CC2C(CC1OC)C(=O)C(C2)CC3CCN(CC3)CC4CCCCC4.C(=O)(C(=O)O)O.

UNSPSC 51141591 Donepezil oxalate is a Commodity code that nominally identifies a specific pharmaceutical active ingredient, but recent state and local procurement activity under this code shows a significant mismatch. The single recent opportunity posted — Seminole County, Florida's IFB for Naloxone and Safe Drug Deactivation Systems — involves procurement of emergency overdose-reversal medication and harm-reduction equipment for community health support, not donepezil oxalate (a cholinesterase inhibitor used in Alzheimer's disease treatment). The procurement calls for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building. Vendors must submit bids electronically through the county e-Procurement Portal, include all shipping and delivery costs, carry workers' compensation and commercial general liability insurance, and comply with E-Verify requirements and drug-free workplace certification. The contract offers a two-year initial term with a one-year renewal option and includes a three-month probationary period. Potential FEMA funding introduces additional compliance requirements tied to environmental regulations. Pricing is fixed-fee with award based on competitive bid.

The code shows minimal recent activity aligned with its nominal pharmaceutical scope. Seminole County is the sole identified issuing body in the available opportunities block, and the primary activity appears to concentrate in Florida. The mismatch between the code's name (a specific Alzheimer's medication) and the actual procurement (emergency medical supplies for opioid response) suggests either a tagging error by the soliciting jurisdiction or incomplete alignment between UNSPSC classification and the goods actually being bought. Firms pursuing pharmaceutical or medical-supply contracts under this code should verify actual state and local demand through direct outreach to health departments, counties, and emergency-services jurisdictions rather than relying on the code's nominal scope to guide opportunity targeting.